Washington-based synthetic biology company AbSci has received an investment of an undisclosed amount from Merck Global Health Innovation Fund.
The investment is part of Merck’s initiative to invest in “Next Horizon” technologies that have the potential to disrupt the biopharmaceutical industry. The partnership will focus on the development of Denovium Engine, a deep learning artificial intelligence platform that AbSci took over in January 2021, and improving AbSci’s core drug discovery capabilities, such as non-standard amino acid technologies.
Founded in 2011, AbSci’s protein discovery and printing platform, SoluPro, is used to design soluble complex proteins and cell lines in a single efficient process. In January 2021, it acquired AI startup Denovium Inc. to leverage the latter’s capabilities in drug discovery and cell line development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.